Reliable potency assessment is essential for CAR-T and CAR-NK therapies, yet most current assays measure only IFN-γ, offering a limited view of engineered cell function.
This application note presents a high-throughput workflow that combines R&D Systems™ Luminex Multiplex Assays with Simple Plex™ Immunoassayson the Ella™ platform to profile cytokines, chemokines, and effector proteins during antigen-specific killing.
What This Application Note Demonstrates:
Using TcBuster™-engineered CD19-CAR-T and CAR-NK cells, the study:
- Quantifies 123 secreted analytes
- Defines distinct secretion signatures
- Reveals donor variability
- Identifies key biomarkers tied to potency
Cross-Platform Validation for Potency Assays
Cross-platform validation demonstrates strong agreement between Luminex and Simple Plex, enabling a streamlined path from broad discovery to focused multi-analyte potency assays.
